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Background: It has been hypothesized that a long-term response to cardiac resynchronization therapy
(CRT) could correlate with myocardial viability in patients with left ventricular (LV) dysfunction.
Contractile reserve and viability in the region of the pacing lead have not been investigated in regard
to acute response after CRT. Methods: Fifty-one consecutive patients with advanced heart failure, LV
ejection fraction ≤ 35%, QRS duration > 120 ms, and intraventricular asynchronism ≥ 50 ms were
prospectively included. The week before CRT implantation, the presence of viability was evaluated
using dobutamine stress echocardiography. Acute responders were defined as a ≥15% increase in
LV stroke volume. Results: The average of viable segments was 5.8 ± 1.9 in responders and 3.9 ± 3
in nonresponders (P = 0.03). Viability in the region of the pacing lead had an excellent sensitivity
(96%), but a low specificity (56%) to predict acute response to CRT. Mitral regurgitation (MR) was
reduced in 21 patients (84%) with acute response. The presence of MRwas a poor predictor of response
(sensibility 93% and specificity 17%). However, combining the presence of MR and viability in the
region of the pacing lead yields a sensibility (89%) and a specificity (70%) to predict acute response
to CRT. Conclusion: Myocardial viability is an important factor influencing acute hemodynamic
response to CRT. In acute responders, significant MR reduction is frequent. The combined presence
of MR and viability in the region of the pacing lead predicts acute response to CRT with the best
accuracy. (ECHOCARDIOGRAPHY, Volume **, ******** ****)
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Cardiac resynchronization therapy (CRT) im-
proves ventricular dyssynchrony, and in term
is associated with an improvement in symp-
toms and prognosis in patients with severe
heart failure.1–6 Echocardiographic assessment
of the acute hemodynamic response to CRT
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predicts long-term clinical outcome in both is-
chemic and nonischemic cardiomyopathy.7 Af-
ter CRT, about 50% of patients have an acute
increase in stroke volume ≥15% and are iden-
tified as acute responders.8 An acute increase
in stroke volume is related to reduction of left
ventricle (LV) dyssynchrony and correspond-
ing stress–strain disparities and inefficient con-
traction of the ventricle.9 Resynchronization of
the LV improved coordinated timing of the me-
chanical activation of papillary muscles and
appears to be the main mechanistic contribu-
tor to immediate MR reduction and increase
in stroke volume.10–17 Response to CRT might
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be modulated by the presence of functional
mitral regurgitation before implantation. In
the CARE-HF study, it was shown that pa-
tients whose conditions did not improve were
likely to have no significant mitral regurgita-
tion as compared with responders.18 However,
the presence of MR seems not to predict acute
response to CRT.8 To date, the main approach
identifying CRT candidates has been QRS du-
ration and mechanical dyssynchrony.19–21 How-
ever, between 30% and 40% of patients with
congestive heart failure and QRS >120 ms
do not clinically improve after CRT.6,22 More-
over, even in patients with QRS >120 ms and
significant intraventricular asynchronism re-
sponse to CRT may not occur,23 CRT nonre-
sponse is likely a diverse phenomenon. Con-
tractile reserve may represent a key element
in the resynchronization process. Because elec-
trical conduction and regional wall thickening
are influenced by the extent of myocardial fibro-
sis, it has been hypothesized that a long-term
response to CRT could correlate with myocar-
dial viability in patients with LV dysfunction.
Using nuclear5,6 myocardial perfusion imag-
ing (2C1Ti),24,25 magnetic resonance imaging
(MRI),23,26 or dobutamine stress echocardiog-
raphy (DSE),27–31 studies have demonstrated
the importance of LV viability in predicting re-
sponse to CRT. Furthermore, scar tissue in the
LV pacing lead region may prohibit response to
CRT.32 However, contractile reserve and viabil-
ity in the region of the pacing lead have not
been investigated in regard to acute response
after CRT. We therefore hypothesized that the
combined presence of viability in the region of
the pacing lead and MR is the best echocar-
diographic parameter to predict acute response
following CRT.
Methods
From May 2005 to March 2008, 51 patients
(mean age 66 ± 11 years, 35 (67%) male) pro-
vided informed consent and were prospectively
enrolled. Inclusion criteria were as follows: (1)
NYHA functional classes III and IV heart fail-
ure, (2) QRS duration ≥120 ms, (3) chronic
LV systolic dysfunction (LV ejection fraction
≤ 35%), (4) basal LV dyssynchrony ≥50 ms,
(5) optimal medical treatment for heart fail-
ure including angiotensin-converting enzyme
inhibitors or AT1 receptor antagonists diuret-
ics, beta-receptor blockers and spironolactone
when tolerated, and (6) sinus rhythm. Pa-
tients with recent myocardial infarction, with
coronary revascularization (<6 months), and
presenting standard contraindications to DSE
were excluded. All patients underwent coro-
nary angiograms before implantation to ex-
clude treatable ischemic heart disease. Etiology
was considered ischemic in the presence of sig-
nificant coronary artery disease (≥50% stenosis
in one or more of the major epicardial coronary
arteries) and/or a history of myocardial infarc-
tion or prior revascularization. All patients pro-
vided informed consent, and the study protocol
was approved by local ethics committee.
Study Design
The patients underwent a clinical examina-
tion, a 12-lead electrocardiography (ECG), and
a resting and DSE, within the week before
CRT implantation. Resting echocardiography
was also performed within 24 hours follow-
ing device placement. Acute responders to CRT
were defined as a ≥15% increase in LV stroke
volume.8
Echocardiographic Assessment
Echocardiographic measurements were per-
formed by two observers blinded to patients’
status using Philips Sonos 5500 or 7500 instru-
ment with a 2.5-MHz transducer (Philips Med-
ical Systems, Amsterdam, The Netherlands).
LV volumes and ejection fraction were mea-
sured using the modified biplane Simpson’s
rule. LV stroke volume was calculated by mul-
tiplying the LV outflow tract area by the LV
outflow tract velocity–time integral measured
by pulsed-wave Doppler.
The proximal isovelocity surface area (PISA)
was used to assess the MR severity and to
measure the effective regurgitant orifice (ERO)
area and regurgitant volume.33 Aortic and pul-
monary Doppler flows were recorded in the
pulsed mode from the apical four-chamber view
and parasternal short-axis view, respectively.
Aortic and pulmonary ejection delays were de-
fined as the delay between the onset of the QRS
complex on the surface ECGand the onset of the
aortic and pulmonary waves. The interventric-
ular delay was defined as the time difference
between the aortic and pulmonary electrome-
chanical delay.34
Intraventricular Asynchronism Measurement
Tissue Doppler imaging (TDI) was performed
in the pulsed-wave Doppler mode from apical
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views to assess longitudinal myocardial re-
gional function, analyzing the septal, inferior,
lateral, anterior, and posterior walls.34 Velocity
profiles were recorded with a sample volume
placed in the middle of the basal segment of
each wall. Gain and filters were adjusted as
needed to eliminate background noise and to
allow for a clear tissue signal. TDI signals were
recorded at a sweep of 100mm/s. The electrome-
chanical delay defined as the delay between
the onset of the QRS complex on the surface
ECG and the onset of the systolic TDI wave was
measured by MS or PG. Intraventricular asyn-
chronism was defined as the time difference be-
tween the shortest and longest electromechan-
ical delay among the five LV walls.34
Assessment of Contractile Reserve
All patients underwent DSE according to
a low-dose infusion protocol. The patients re-
ceived 5, 10, 15, and 20 µg/kg per minute of
dobutamine in a 3-minute stage, with echocar-
diographic images recorded at each stage.35,36
Heart rate and blood pressure were moni-
tored during each stage. Criteria for stopping
the dobutamine infusion included (1) hypoten-
sion (systolic blood pressure < 90 mmHg),
(2) angina, (3) significant arrhythmias (atrial
fibrillation, bigeminy, ventricular tachycardia),
and (4) attainment of 85% maximal predicted
heart rate. The regional wall motion was as-
sessed by the 16-segment model recommended
by the American Society of Echocardiography.37
Thus, a normal or hyperkinetic segment was
graded as 1, hypokinetic as 2, akinetic as 3,
and dyskinetic as 4. The stress images at the
dobutamine dose showing the maximum aug-
mentation of wall motion were compared with
baseline images. A segment was considered to
have contractile reserve if after dobutamine the
wall motion improved by one grade. Viability in
the region of the LV pacing lead was defined
as the presence of viability in two contiguous
segments. DSE was interpreted by MS or PG.
CRT Implantation and LV Lead Position
A coronary sinus venogram was obtained us-
ing balloon catheter, followed by the insertion
of the LV pacing lead (Guidant Corporation,
St Paul, NM or Medtronic Inc., Minneapolis,
MN, USA) in the coronary sinus. The preferred
position was a lateral or posterolateral vein.
The right atrial and ventricular leads were
positioned conventionally. All leads were con-
nected to a dual-chamber biventricular pac-
ing (Guidant Corporation, or Medtronic Inc.,
Milwaukee, WI, USA). One day after implanta-
tion, the LV lead position was assessed from a
chest x-ray. Using the frontal and lateral views
(scored anterior, lateral, or posterior), we deter-
mined the LV lead locations.38
Statistical Analysis
Results are expressed as mean ± SD or per-
centages unless otherwise specified. The pa-
tients were separated into two groups (respon-
ders and nonresponders) according to the early
post-CRT change in LV stroke volume (>15%).8
Interobserver and intraobserver variabilities
for the measurement of inter- and intraventric-
ular asynchronism as well as for the quantifi-
cation of the wall motion score index (WMSI)
were determined from the analysis of Doppler
echocardiographic images of 15 randomly se-
lected patients by two independent observers
(MS and PG). The results were compared with a
one-way analysis of variance, Pearson’s correla-
tion coefficient, and the Bland–Altmanmethod.
Baseline data of the responder group versus the
nonresponder group were compared for statis-
tical significance using the t-test or chi-square
test, as appropriate. Baseline and post-CRTMR
severity were compared within groups using
the paired-t test or chi-square test, as appropri-
ate. Sensitivity and specificity for prediction of
CRT response were determined for various cut-
off values of the echocardiographic parameters
using receiver-operating characteristic curves.
Linear regression analyses were used to eval-
uate the relationship between CRT response,
assessed as the percentage of change in LV




The day after CRT implantation, 28 patients
(55%) were responders and compared to non-
responders (n = 23, 45%) there was no signifi-
cant difference with regards to baseline demo-
graphic and clinical characteristics (Table I).
However, the patients in the nonresponder
group tended to have higher LV stroke volume
(46 ± 2 ml vs. 39 ± 12 ml, P = 0.06). The num-
ber of akinetic segments in each patient ranged
from 1 to 15 segments (mean 9.5 ± 3.3). De-
vice implantation was successful in all patients
and one patient developed pneumothorax after
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TABLE I
Demographic and Clinical Data
All Patients Responders Nonresponders
Variables (n = 51) (n = 28, 55%) (n = 23, 45%) P-Value
Demographic data
Age (years) 66 ± 11 67 ± 10 65 ± 13 0.52
Male, n (%) 35 (69) 19 (68) 16 (70) 0.90
CAD, n (%) 35 (69) 18 (65) 17 (74) 0.46
Clinical data
QRS duration (ms) 161 ± 30 159 ± 27 163 ± 33 0.67
LBBB, n (%) 32 (63) 20 (71) 12 (52) 0.16
RBBB, n (%) 3 (6) 2 (7) 1 (4) 0.67
IVCD, n (%) 8 (17) 3 (12) 5 (22) 0.36
PR (ms) 184 ± 41 176 ± 32 194 ± 49 0.14
Pre-CRT pacing, n (%) 8 (16) 3 (11) 5 (22) 0.28
NYHA III/IV, n (%) 35 (69)/16 (31) 21 (75)/7 (25) 14 (60)/9 (39) 0.28
Medication
Diuretic, n (%) 48 (94) 26 (93) 22 (96) 0.67
β-blockers, n (%) 48 (94) 26 (94) 22 (96) 0.67
ACEi, n (%) 35 (69) 19 (68) 16 (70) 0.90
AR blockers, n (%) 15 (30) 9 (33) 6 (26) 0.58
Digoxin, n (%) 14 (27) 5 (18) 9 (39) 0.09
Spironolactone, n (%) 33 (63) 15 (54) 17 (74) 0.14
CAD = coronary arteries disease; LBBB = left bundle branch block; RBBB = right bundle branch block; IVCD =
intraventricular conduction defect; ACEi = angiotensin-converting enzyme inhibitors; AR = angiotensin receptors.
CRT implantation. LV pacing threshold was not
different between responders and nonrespon-
ders (1.18 ± 0.70 vs. 1.75 ± 0.5, P = 0.17). In
the subgroup of patients with CAD, no patients
experienced angina, electric, or regional wall
motion modification at peak stress (20 µg/kg
per minute) suggesting ischemia.
Reproducibility of Asynchronism and WMSI
There were excellent correlations (r ≥ 0.96)
between intra- and interobserver analyses of
viability in the region of the pacing lead and
for WMSI. Intra- and interobserver relative
differences were <3% for all parameters. The
Bland–Altman method showed excellent agree-
ment between inter- and intraobserver mea-
surements in both low and high values of asyn-
chronism or WMSI.
Contractile Reserve to Predict Response
All patients completed the DSE protocol
without complications. During low-dose dobu-
tamine infusion, responders tended to have less
akinetic segments (7.7 ± 3 vs. 9 ± 3, P = 0.06)
and a significantly higher number of viable seg-
ments (5.8 ± 1.94 vs. 3.87 ± 2.99, P = 0.007)
than nonresponders. The presence of more than
four viable segments and viability in the region
of the pacing lead were statistically more fre-
quent in responders (96% vs. 52%, P < 0.0001
and 96% vs. 43%, P < 0.0001, respectively)
(Table II). LV stroke volume changes after CRT
were directly related to the improvement in
WMSI during dobutamine infusion (r = 0.45,
P = 0.0012) (Fig. 1A). A similar correlation was
also observed between the change in ERO af-
ter CRT and the improvement of WMSI during
DSE (r = 0.41, P = 0.0057) (Fig. 1B).
Global Viability and Local Viability versus
Response to CRT
Among patients with local viability (i.e., via-
bility in the region of the pacing lead), 27 (73%)
were responders corresponding to 96% of all re-
sponders. Conversely, in patients with global
viability (i.e., ≥ 4 viable segments) without lo-
cal viability (n = 4), only one patient (25%) was
identified as a responder. In the absence of lo-
cal and global viabilities, all patients (n = 10,
100%) were nonresponders (Fig. 2).
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TABLE II
Echocardiographic Data
All Patients Responders Nonresponders
Variables (n = 51) (n = 28, 55%) (n = 23, 45%) P-Value
LV geometry and function
LV end-diastolic volume (ml) 214 ± 67 211 ± 69 217 ± 65 0.75
LV end-systolic volume (ml) 178 ± 63 177 ± 67 180 ± 67 0.90
LV end-diastolic diameter (mm) 67 ± 8 66 ± 8 68 ± 8 0.26
LV end-systolic diameter (mm) 59 ± 9 61 ± 9 57 ± 3 0.13
End-systolic SI (%) 63 ± 9 64 ± 9 63 ± 9 0.87
End-diastolic SI (%) 69 ± 9 66 ± 2 65 ± 2 0.82
LV stroke volume (ml) 42 ± 12 39 ± 12 46 ± 2 0.06
LV ejection fraction (%) 19 ± 7 18 ± 8 19 ± 6 0.70
Asynchronism
Interventricular (ms) 45 ± 27 43 ± 26 47 ± 28 0.63
Intraventricular (ms) 83 ± 25 87 ± 25 79 ± 24 0.23
No. of akinetic segments
Rest 9.5 ± 3 9.4 ± 3 10 ± 3 0.26
Dobutamine 8.4 ± 3 7.7 ± 3 9 ± 3 0.06
Wall motion score index
Rest 3.5 ± 0.4 3.41 ± 0.42 3.55 ± 0.25 0.15
Dobutamine 3.1 ± 0.5 2.97 ± 0.41 3.25 ± 0.48 0.03
Viability
No. of viable segments 4.9 ± 3 5.8 ± 1.94 3.87 ± 2.99 0.007
More than viable segments, n (%) 39 (76) 27 (96) 12 (52) <0.0001
Viability in the region of the lead, n (%) 37 (73) 27 (96) 10 (43) <0.0001
Lead placement
Posterior, n (%) 34 (66) 20 (71) 14 (61) 0.83
Lateral, n (%) 15 (30) 8 (29) 7 (30) 0.87
Anterior, n (%) 2 (4) – 2 (9) –
LV = left ventricular; ED = end-diastolic; ES = end-systolic; SI = sphericity index.
Impact of Viability and Mitral Regurgitation
on CRT Response
The prevalence of MR between responders
and nonresponders was not statistically dif-
ferent before and after CRT (pre-CRT: 93%
vs. 83%, P = 0.26, post-CRT: 83% vs. 85%,
P = 0.96). Moreover, there was no significant
difference in baseline MR severity between
groups (Fig. 3A), and whereas in responders
ERO and regurgitant volume were significantly
reduced following CRT, there was no significant
change in nonresponders (Fig. 3A and B). In-
deed, in responders, ERO was reduced by 57 ±
24% (from 18 ± 12 mm2 to 8 ± 8 mm2, P =
< 0.001). The percentage of patients with se-
vere MR (ERO ≥ 20 mm2) was also not sta-
tistically different between groups before CRT
(Fig. 3C). Only four responders had no MR be-
fore CRT. In receiver-operating characteristics
curves, the presence of MR, as well as the pres-
ence of viability on the region of the pacing
lead, was associated with excellent sensitivity
(93%and 96%) butwith low specificity (17%and
56%) in predicting acute CRT response. Com-
bining the presence of MR and viability in the
region of the pacing lead yield the best combi-
nation of sensitivity and specificity (89%, 70%)
(Fig. 4).
Discussion
Themain finding of the present study showed
that for acute benefit in ischemic and non-
ischemic cardiomyopathies, CRT requires the
presence of myocardial viability. A direct re-
lationship between improvement in WMSI as
assessed during low-dose dobutamine infusion
and the improvement in LV stroke volume and
reduction in ERO after CRT was described.
This study shows the ability of DSE to predict
acute response to CRT in patients with drug-
refractory systolic heart dysfunction and signi-
ficative intraventricular dyssynchrony.
Lastly, the combined presence of viability in
the region of the pacing lead defined as viability
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Figure 1. A. Correlation between changes in WMSI
(rest/dobutamine) and changes in stroke volume after CRT.
B.Correlation between changes inWMSI (rest/dobutamine)
and changes in ERO after CRT.
in two contiguous segments and MR predicts
acute response with the best accuracy.
Effect of Global Viability
Wall motion response during dobutamine
infusion is useful in predicting functional
myocardial recovery in patients with ischemic
and nonischemic heart diseases.35,39–41 The
clinical response to treatments such as β-
blockade or revascularization in patients with
LV systolic dysfunction has been shown to be
dependent on the presence and extent of viable
myocardium. Although CRT improves cardiac
function by other mechanisms than revascu-
larization or by up-regulation of sarcoplasmic
reticulum calcium ATPase (beta-blockade), the
relationship between viability and CRT bene-
fit still holds.27–31 When myocytes have been
supplanted by replacement fibrosis because of
cell death and interstitial remodeling, medical
Figure 2. Percentage of responders to CRT for four different
patient categories based on the presence or the absence of
viability in the region of the pacing lead (local +/local −)
in combination with the presence or the absence of four or
more viable segments (global +/global −).
therapy and CRT may not improve LV func-
tion. However, studies evaluating the relation-
ship between CRT and myocardial viability are
scarce. Ypenburg et al. evaluated and demon-
strated that besides the presence of LV dyssyn-
chrony, myocardial contractile reserve (result-
ing in a ≥7.5% increase in LV ejection fraction
during dobutamine infusion) predicts LV re-
verse remodeling and improvement in LV
function, 6months after CRT implantation. An-
other study in 67 patients (34% ischemic) re-
vealed that the presence of contractile myocar-
dial reserve was an independent predictor of
event-free survival after CRT. Using a cutoff
value of 25% increase in dobutamine LV ejec-
tion fraction exhibits a sensitivity of 70% and a
specificity of 62% for predicting major cardiac
events.31 Hummel et al., in 21 CRT patients
(100% ischemic), evaluated myocardial viabil-
ity by myocardial contrast echocardiography.30
The LV systolic performance was assessed by
echocardiography on the day after implanta-
tion. In that study, acute improvement in LV
stroke volume was significantly correlated with
the degree of viability as determined by the per-
fusion score index.30 In our study, we related
global viability to acute response to CRT. Im-
provement in LV stroke volume correlated (r =
0.45, P = 0.0012) with improvement in WMSI
during the dobutamine test. Moreover, respon-
ders showed a greater number of viable seg-
ments (5.8 ± 1.94 vs. 3.87 ± 2.99, P = 0.007).
The presence of more than four viable seg-
ments predicted acute response to CRT with a
high sensitivity but with a low specificity.
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Figure 3. Quantification of MR in responders and non-
responders before and after CRT. A. Changes in ERO; B.
Changes in regurgitant volume; C. Changes in the presence
of severe MR (≥20 mm2)
Role of Viability in the Region of the Pacing
Lead
Using contrast-enhanced MRI, Bleeker et al.
demonstrated in 40 patients (100% ischemic)
that CRT did not reduce LV dyssynchrony in
patients with transmural scar tissue in the
posterolateral LV segments, resulting in clini-
cal and echocardiographic nonresponse to CRT.
Only 14% of patients with a posterolateral scar
showed response to CRT. Even in the subset
of patients with intraventricular asynchrony
and postero-lateral scar, the response rate was
low (n = 2, 18%).32 Ypenburg et al. recently
observed in 31 CRT patients that responders
showed an increase in strain in the region of
the LV pacing lead during low-dose dobutamine
infusion while nonresponders had no contrac-
tile reserve (absence of an increase in strain).27
Furthermore, Lim et al. demonstrated that only
patients (n = 19) with contractile reserve in
the LV target site for pacing (lateral, postero-
lateral) presented a decrease in LV dyssyn-
chrony with CRT.28 The authors also showed
that the mean increase of LV stroke volume
was greater in patients with contractile reserve
(22% vs. 0%). The number of viable segments in
each wall showing viability (i.e., contractile re-
serve) was however not stated in that study.
In line with these results, the present study
demonstrated that acute responders to CRT
showed viability in the region of the pacing lead
Figure 4. Performance of viability and MR evaluated be-
fore CRT in predicting acute response.
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significantly more often than nonresponders. It
appears likely that viability of the paced seg-
ments is the crucial factor mediating the influ-
ence of viability (local viability vs. global) on re-
sponse to CRT. Of interest, in the present study,
in the absence of viability in the region of the
pacing lead, three patients (75%) did not show
acute response even if they had more than four
viable segments. Moreover, one patient (50%)
was a responder in the presence of only three
viable segments (i.e., only in the region of the
pacing lead). Therefore, it is likely that acute
improvement in LV stroke volume after biven-
tricular pacing is driven mainly by viability
of the paced myocardial segments. However,
viability in the region of the pacing lead pre-
dicts acute response with an excellent sensitiv-
ity (96%) but with a low specificity (56%). Com-
bining viability in the region of the pacing lead
andMR predicts acute response after CRT with
the best accuracy suggesting that reduction of
MR is almost mandatory in acute responders.
The principal mechanism explaining this acute
change in LV stroke volume is probably, at least
in part, related to the diminution of functional
MR. CRT appears to increase mitral closing
force, coordinate tethering forces on papillary
muscles, and increase the leaflet coaptation sur-
face to reduce MR.13–15 Previous studies have
reported conflicting results regarding the pres-
ence and severity of MR and response to CRT.
Of interest, none of those studies have evalu-
ated LV viability and its relationship with MR
presence or severity and LV remodeling.42–45 In
our study, only four responders did not have
MR in pre-CRT. Of interest, those patients had
nonischemic cardiomyopathy, viability in the
region of the pacing lead, and amean of 8 viable
segments, which suggests that acute response
may occur in patients without MR before CRT
but only in the presence of substantial viable
myocardium.
Clinical Implications
Our present results confirm earlier sugges-
tions that the absence of viability in the region
of the LV pacing lead may prohibit response to
CRT. This study focuses on acute response and
its relationship with viability and MR. Even
if acute response after CRT underestimates
long-term effects, identification of such patients
may be important since acute hemodynamic re-
sponse to CRT predicts long-term clinical out-
come and acute responders may represent more
than 70% of all eventual responders.8 Our re-
sults support that the presence of viability in
the region of the pacing lead is a better predic-
tor of acute response over the burden of global
viability. Also, in the presence of local viability,
a decrease of MR seems mandatory in most pa-
tients with acute response. Of interest, in our
study, the criterion used to define the presence
of “significant” viability in the region of the LV
pacing lead (presence of viability in two con-
tiguous segments) is simple, rapid, and easily
applicable in the context of clinical evaluation
before CRT. This underlines the importance of
assessing local viability in order to guide LV
positioning. The region of myocardium without
viability should be avoided as a final resting
place for LV lead placement to maximize the
possibility of therapeutic benefit.
Study Limitations
These results should be regarded cautiously,
and some limitations should be underlined.
First, the lack of difference between responders
and nonresponders regarding the presence of
CAD may be the result of the small number
of patients, and results should be confirmed by
a larger study. Second, although the difference
was not statistically different, more nonrespon-
ders took digoxin and spironolactone than re-
sponders and showed a higher incidence of class
IV NYHA; therefore, because of the sample size
(n = 51) and the heterogeneity of the popula-
tion studied, those data should be interpreted
cautiously until confirmed by suitably powered
clinical trials that are undoubtedly needed.
Third, dyssynchrony was defined by longitudi-
nal tissue Doppler imaging using a cutoff value
of 50 ms as inclusion criterion. Combining lon-
gitudinal and radial dyssynchrony indices as
inclusion criteria could have been helpful in
choosing a more homogenous population prone
to CRT response.46
Conclusion
In this study, we demonstrated that myocar-
dial viability is an important factor influenc-
ing acute hemodynamic response to CRT. In
acute responders, significant MR reduction is
frequent. The combined presence of MR and vi-
ability in the region of the pacing lead defined
as two contiguous viable segments, determined
by DSE predicts acute response to CRT with
the best accuracy.
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